Published in Circ Res on December 01, 1993
Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J (1998) 3.83
Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov (2009) 3.12
Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium. J Physiol (2000) 2.59
Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart. J Physiol (2004) 2.09
Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm (2011) 2.01
Voltage-dependent inactivation of the human K+ channel KvLQT1 is eliminated by association with minimal K+ channel (minK) subunits. J Physiol (1998) 1.88
KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias. Proc Natl Acad Sci U S A (1997) 1.70
Long QT and ventricular arrhythmias in transgenic mice expressing the N terminus and first transmembrane segment of a voltage-gated potassium channel. Proc Natl Acad Sci U S A (1998) 1.64
Targeted deletion of kcne2 impairs ventricular repolarization via disruption of I(K,slow1) and I(to,f). FASEB J (2008) 1.54
Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol (1996) 1.50
A rapidly activating sustained K+ current modulates repolarization and excitation-contraction coupling in adult mouse ventricle. J Physiol (1997) 1.38
Localization of the Kv1.5 K+ channel protein in explanted cardiac tissue. J Clin Invest (1995) 1.35
Can inhibition of IKur promote atrial fibrillation? Heart Rhythm (2008) 1.31
Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes. J Physiol (2007) 1.22
K+ current changes account for the rate dependence of the action potential in the human atrial myocyte. Am J Physiol Heart Circ Physiol (2009) 1.17
Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol (1996) 1.17
Characterization of a voltage-gated K+ channel beta subunit expressed in human heart. Proc Natl Acad Sci U S A (1995) 1.16
Impact of sarcoplasmic reticulum calcium release on calcium dynamics and action potential morphology in human atrial myocytes: a computational study. PLoS Comput Biol (2011) 1.15
Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys J (1995) 1.14
Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol (2004) 1.11
The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization. Br J Pharmacol (2007) 1.08
Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. EMBO Mol Med (2015) 1.08
Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol (2008) 1.08
Effect of androgen deficiency on mouse ventricular repolarization. J Physiol (2003) 1.03
Hydrogen peroxide modulates the Kv1.5 channel expressed in a mammalian cell line. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.99
Inter-subject variability in human atrial action potential in sinus rhythm versus chronic atrial fibrillation. PLoS One (2014) 0.98
Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann N Y Acad Sci (2008) 0.97
Molecular correlates of the calcium-independent, depolarization-activated K+ currents in rat atrial myocytes. J Physiol (1999) 0.97
Identification, cloning and expression of rabbit vascular smooth muscle Kv1.5 and comparison with native delayed rectifier K+ current. J Physiol (1999) 0.96
Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state--docking and computer simulations of a homology model. Biophys J (2007) 0.95
Evidence for multiple open and inactivated states of the hKv1.5 delayed rectifier. Biophys J (1998) 0.95
Overexpression of nerve growth factor in the heart alters ion channel activity and beta-adrenergic signalling in an adult transgenic mouse. J Physiol (1998) 0.94
Opening and closing of KCNKO potassium leak channels is tightly regulated. J Gen Physiol (2000) 0.90
How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation? J Atr Fibrillation (2008) 0.90
TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes. Cell Physiol Biochem (2011) 0.90
Four and a half LIM protein 1C (FHL1C): a binding partner for voltage-gated potassium channel K(v1.5). PLoS One (2011) 0.90
Atrial selectivity of antiarrhythmic drugs. J Physiol (2013) 0.89
Impact of ancillary subunits on ventricular repolarization. J Electrocardiol (2007) 0.89
Transient outward K+ current reduction prolongs action potentials and promotes afterdepolarisations: a dynamic-clamp study in human and rabbit cardiac atrial myocytes. J Physiol (2012) 0.89
Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol (1995) 0.88
Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol (2012) 0.88
4-aminopyridine activates potassium currents by activation of a muscarinic receptor in feline atrial myocytes. J Physiol (1997) 0.88
Adrenergic control of the ultrarapid delayed rectifier current in canine atrial myocytes. J Physiol (1999) 0.87
Ion channel trafficking: a new therapeutic horizon for atrial fibrillation. Heart Rhythm (2010) 0.86
Effects of diltiazem and nifedipine on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes. Br J Pharmacol (2005) 0.86
KCNE Regulation of K(+) Channel Trafficking - a Sisyphean Task? Front Physiol (2012) 0.85
Characterization of a beta-adrenergically inhibited K+ current in rat cardiac ventricular cells. J Physiol (1996) 0.85
There and back again: Iterating between population-based modeling and experiments reveals surprising regulation of calcium transients in rat cardiac myocytes. J Mol Cell Cardiol (2015) 0.85
Open channel block of Kv1.5 currents by citalopram. Acta Pharmacol Sin (2010) 0.85
PKC and AMPK regulation of Kv1.5 potassium channels. Channels (Austin) (2015) 0.84
Blockade of Kv1.5 channels by the antidepressant drug sertraline. Korean J Physiol Pharmacol (2016) 0.84
Ion Channels in the Heart. Compr Physiol (2015) 0.83
Novel pharmacological targets for the rhythm control management of atrial fibrillation. Pharmacol Ther (2011) 0.83
Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels. Br J Pharmacol (2005) 0.82
Electrophysiological characterization of three non-synonymous single nucleotide polymorphisms (R87Q, A251T, and P307S) found in hKv1.5. Pflugers Arch (2006) 0.82
Markov models of use-dependence and reverse use-dependence during the mouse cardiac action potential. PLoS One (2012) 0.82
Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel. Br J Pharmacol (2009) 0.82
Blockade of Kv1.5 by paroxetine, an antidepressant drug. Korean J Physiol Pharmacol (2015) 0.82
Effects of human atrial ionic remodelling by β-blocker therapy on mechanisms of atrial fibrillation: a computer simulation. Europace (2014) 0.81
Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels. Br J Pharmacol (1999) 0.81
Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2. Br J Pharmacol (1996) 0.80
Isoenzyme-specific regulation of cardiac Kv1.5/Kvβ1.2 ion channel complex by protein kinase C: central role of PKCβII. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.80
Cardiac ion channels. Channels (Austin) (2015) 0.80
Pergolide block of the cloned Kv1.5 potassium channels. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.79
Potassium currents in the heart: Functional roles in repolarization, arrhythmia and therapeutics. J Physiol (2016) 0.79
Emerging concepts in the pharmacogenomics of arrhythmias: ion channel trafficking. Expert Rev Cardiovasc Ther (2010) 0.78
Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol (2001) 0.78
Differential expression of potassium channels and abnormal conduction in experimental tachycardia-induced heart failure. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.78
The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes. Br J Pharmacol (1999) 0.78
Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology. Card Electrophysiol Clin (2016) 0.78
Effects of the chromanol HMR 1556 on potassium currents in atrial myocytes. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.77
Effects of propafenone on K currents in human atrial myocytes. Br J Pharmacol (1999) 0.77
Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea? Pflugers Arch (2014) 0.77
The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation. Heart Rhythm (2015) 0.77
Rate-dependent blockade of a potassium current in human atrium by the antihistamine loratadine. Br J Pharmacol (1999) 0.76
Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.76
Atrial electrical remodeling by rapid pacing in the isolated rabbit heart: effects of Ca++ and K+ channel blockade. J Interv Card Electrophysiol (1998) 0.76
Non-specific action of methoxamine on Ito, and the cloned channels hKv 1.5 and Kv 4.2. Br J Pharmacol (1999) 0.76
Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation. Br J Pharmacol (2014) 0.76
Cross-talk between beta(1)-adrenoceptors and ET(A) receptors in modulation of the slow component of delayed rectifier K(+) currents. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.75
Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.75
How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation? J Atr Fibrillation (2008) 0.75
Serum positive for the autoantibody against the β(1)-adrenoceptor from Chinese patients with congestive heart failure decreases I(ss) in mouse cardiac myocytes. Clin Dev Immunol (2011) 0.75
Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. Br J Pharmacol (2010) 0.75
Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J Cardiovasc Pharmacol (2012) 0.75
Pharmacogenomics of cardiovascular complications in diabetes and obesity. Recent Pat Biotechnol (2014) 0.75
Improved functional expression of human cardiac kv1.5 channels and trafficking-defective mutants by low temperature treatment. PLoS One (2014) 0.75
Cardiac Delayed Rectifier Potassium Channels in Health and Disease. Card Electrophysiol Clin (2016) 0.75
New aspects of HERG K⁺ channel function depending upon cardiac spatial heterogeneity. PLoS One (2014) 0.75
Modeling Electrophysiological Coupling and Fusion between Human Mesenchymal Stem Cells and Cardiomyocytes. PLoS Comput Biol (2016) 0.75
The role of the renin-angiotensin system blocking in the management of atrial fibrillation. J Drug Assess (2012) 0.75
Cardiovascular Action of Insulin in Health and Disease: Endothelial L-Arginine Transport and Cardiac Voltage-Dependent Potassium Channels. Front Physiol (2016) 0.75
Advances in the Pharmacological Treatment of Atrial Fibrillation. Curr Med Lit Cardiol (2010) 0.75
Functional Characterization of Human Stem Cell-Derived Cardiomyocytes. Curr Protoc Pharmacol (2014) 0.75
Genistein and tyrphostin AG556 decrease human atrial ultra-rapidly activating delayed rectifier potassium current by inhibiting EGFR tyrosine kinase. Br J Pharmacol (2017) 0.75
Mathematical models of canine right and left atria cardiomyocytes. J Zhejiang Univ Sci B (2010) 0.75
Rate-Dependent Role of IKur in Human Atrial Repolarization and Atrial Fibrillation Maintenance. Biophys J (2017) 0.75
Detailed Anatomical and Electrophysiological Models of Human Atria and Torso for the Simulation of Atrial Activation. PLoS One (2015) 0.75
Empirical correlation of triggered activity and spatial and temporal re-entrant substrates with arrhythmogenicity in a murine model for Jervell and Lange-Nielsen syndrome. Pflugers Arch (2009) 0.75
Patch-Clamp Recording from Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Improving Action Potential Characteristics through Dynamic Clamp. Int J Mol Sci (2017) 0.75
Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med (1997) 4.51
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med (2000) 4.27
Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation (1999) 4.24
Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am J Physiol (1998) 3.41
Mechanism of propranolol withdrawal phenomena. Circulation (1979) 2.66
Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res (1996) 2.50
Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res (1997) 2.38
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation (2001) 2.27
Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res (1993) 2.02
Potential molecular basis of different physiological properties of the transient outward K+ current in rabbit and human atrial myocytes. Circ Res (1999) 1.94
Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation (2000) 1.83
Potential ionic mechanism for repolarization differences between canine right and left atrium. Circ Res (2001) 1.79
Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol (1997) 1.72
Rapid and slow components of delayed rectifier current in human atrial myocytes. Cardiovasc Res (1994) 1.67
Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res (1998) 1.66
Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res (1999) 1.61
Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res (2001) 1.60
Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ Res (1997) 1.57
Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res (1999) 1.56
Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation (1997) 1.51
Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Circulation (1998) 1.50
Mathematical analysis of canine atrial action potentials: rate, regional factors, and electrical remodeling. Am J Physiol Heart Circ Physiol (2000) 1.50
Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. Eur Heart J (2002) 1.50
Transmembrane ICa contributes to rate-dependent changes of action potentials in human ventricular myocytes. Am J Physiol (1999) 1.42
Delayed rectifier outward current and repolarization in human atrial myocytes. Circ Res (1993) 1.35
Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther (1995) 1.34
Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation (1998) 1.33
Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. Circ Res (1998) 1.24
Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. Am J Physiol (1996) 1.22
Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes. Circ Res (1996) 1.20
IK of rabbit ventricle is composed of two currents: evidence for IKs. Am J Physiol (1996) 1.19
Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol (1996) 1.17
Properties, expression and potential roles of cardiac K+ channel accessory subunits: MinK, MiRPs, KChIP, and KChAP. J Membr Biol (2003) 1.16
Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation (1998) 1.15
Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation (1990) 1.13
Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Am J Physiol (1998) 1.12
Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation. Circ Res (1997) 1.12
Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. Circ Res (1996) 1.10
Atrial cell action potential parameter fitting using genetic algorithms. Med Biol Eng Comput (2005) 1.10
Nicotine is a potent blocker of the cardiac A-type K(+) channels. Effects on cloned Kv4.3 channels and native transient outward current. Circulation (2000) 1.10
Mechanisms of inactivation of L-type calcium channels in human atrial myocytes. Am J Physiol (1997) 1.10
Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue. J Pharmacol Exp Ther (1993) 1.08
Alpha-adrenergic control of volume-regulated Cl- currents in rabbit atrial myocytes. Characterization of a novel ionic regulatory mechanism. Circ Res (1995) 1.08
Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study. J Nucl Cardiol (1998) 1.07
Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation (2001) 1.07
Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells. Am J Physiol Heart Circ Physiol (2001) 1.07
Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness. Circulation (1993) 1.07
Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry. Europace (2005) 1.06
Relative role of alkalosis and sodium ions in reversal of class I antiarrhythmic drug-induced sodium channel blockade by sodium bicarbonate. Circulation (1996) 1.06
Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation (2000) 1.03
Minimum Information about a Cardiac Electrophysiology Experiment (MICEE): standardised reporting for model reproducibility, interoperability, and data sharing. Prog Biophys Mol Biol (2011) 1.03
Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol Pharmacol (2001) 1.03
Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res (2001) 1.00
Evidence that outwardly rectifying Cl- channels underlie volume-regulated Cl- currents in heart. Circ Res (1997) 1.00
Method for simultaneous epicardial and endocardial mapping of in vivo canine heart: application to atrial conduction properties and arrhythmia mechanisms. J Cardiovasc Electrophysiol (2001) 0.99
Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther (1993) 0.99
Oxidative preconditioning and apoptosis in L-cells. Roles of protein kinase B and mitogen-activated protein kinases. J Biol Chem (2001) 0.98
Comparative mechanisms of 4-aminopyridine-resistant Ito in human and rabbit atrial myocytes. Am J Physiol (1995) 0.97
Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovasc Res (1981) 0.97
Differences in rate dependence of transient outward current in rabbit and human atrium. Am J Physiol (1992) 0.97
Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res (1992) 0.96
Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther (1984) 0.95
Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther (1997) 0.94
Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation (1999) 0.94
A comparison of transient outward currents in canine cardiac Purkinje cells and ventricular myocytes. Am J Physiol Heart Circ Physiol (2000) 0.93
Repolarization differences between guinea pig atrial endocardium and epicardium: evidence for a role of Ito. Am J Physiol (1991) 0.92
Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C. Circulation (1995) 0.91
Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes. Cardiovasc Res (2000) 0.90
Properties of sodium and potassium currents of cultured adult human atrial myocytes. Am J Physiol (1996) 0.90
Transmembrane chloride currents in human atrial myocytes. Am J Physiol (1996) 0.90
Beta-blockers as antiarrhythmic agents. Handb Exp Pharmacol (2006) 0.90
Adenosine-induced activation of ATP-sensitive K+ channels in excised membrane patches is mediated by PKC. Am J Physiol (1999) 0.89
The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation (1999) 0.89
Experimental amitriptyline intoxication: electrophysiologic manifestations and management. J Cardiovasc Pharmacol (1984) 0.88
Mechanism of action potential prolongation by RP 58866 and its active enantiomer, terikalant. Block of the rapidly activating delayed rectifier K+ current, IKr. Circulation (1996) 0.88
Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Circulation (1995) 0.88
State-dependent barium block of wild-type and inactivation-deficient HERG channels in Xenopus oocytes. J Physiol (2000) 0.87
Artificial intelligence versus logistic regression statistical modelling to predict cardiac complications after noncardiac surgery. Clin Cardiol (1994) 0.87
Sustained outward current observed after I(to1) inactivation in rabbit atrial myocytes is a novel Cl- current. Am J Physiol (1992) 0.87
Adrenergic control of the ultrarapid delayed rectifier current in canine atrial myocytes. J Physiol (1999) 0.87
Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation (1994) 0.87
Multivariate clinical models and quantitative dipyridamole-thallium imaging to predict cardiac morbidity and death after vascular reconstruction. J Vasc Surg (1991) 0.86
Effect of sympathetic tone on ventricular arrhythmias during circumflex coronary occlusion. Am J Physiol (1985) 0.86